Basecamp Raises $140M for Biological AI

Basecamp Research has raised a large Series C to deepen its bet that proprietary biological data can become a durable advantage in AI drug discovery.

What happened

The London-based company raised $140M to train new biological foundation models and advance AI-designed therapeutics.

Basecamp builds models on proprietary biodiversity datasets gathered across diverse biological environments. The aim is to capture evolutionary information that is poorly represented in standard public datasets.

Why it matters

In AI biology, access to differentiated training data may matter as much as model architecture. Public biological databases are powerful, but many companies are training on overlapping datasets.

Basecamp is trying to create an information advantage by collecting data that competitors cannot easily reproduce, then using that dataset to train models for protein and therapeutic design.

The bigger picture

AI drug discovery is increasingly becoming a data-infrastructure race. The most defensible companies may be those that control unique biological datasets, experimental pipelines and validation systems rather than simply relying on general-purpose models.